KARE Rx Portal Information

When your healthcare provider prescribes Licart^® (diclofenac epolamine) topical system 1.3%, you want to receive the medication they selected for you. The KARE Rx Portal helps make that happen.

Instead of taking your prescription to a pharmacy where it may be substituted or delayed, your provider can now send it directly to the KARE Rx Portal. The KARE team helps navigate the prescription process to help ensure you receive Licart as prescribed while also saving you a trip to the pharmacy.

The KARE Team Helps Handle the Details

Once your provider sends your Licart prescription to the KARE Rx Portal, the KARE team will:

Help ensure you receive Licart as prescribed by your healthcare provider
Verify your insurance coverage
Automatically apply eligible copay assistance
Help manage prior authorization, if required, by working with your healthcare provider and insurance company
Coordinate with a participating pharmacy to fill your Licart prescription
Arrange delivery directly to your door with no shipping fees

What to Expect

Step 1: Your prescriber writes you a script for Licart.
Your healthcare provider sends your prescription directly to the KARE Rx Portal.

Step 2: The KARE team gets to work.
The KARE team will process your prescription, verify your insurance information, and determine whether any additional steps are needed. You’ll receive a confirmation text from KARE, and a member of the team may call you if additional insurance information is required.

Step 3: Your Licart prescription is filled.
An independent pharmacy in the KARE network will contact you to collect any applicable copay and fill your Licart prescription.

Prefer to pay out of pocket and not use insurance?
KARE can connect you with the appropriate Licart Direct partner should you prefer to pay out of pocket.

Step 4: Licart is shipped to you.
Your Licart prescription will be shipped directly to your door with no shipping fees.

Read More ↗

INDICATIONS AND USAGE

LICART contains diclofenac epolamine, which is a nonsteroidal anti-inflammatory drug (NSAID), and is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF SERIOUS CARDIOVASCULAR and GASTROINTESTINAL EVENTS

Cardiovascular Thrombotic Events

Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in the treatment and may increase with duration of use.
LICART is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.

Gastrointestinal Bleeding, Ulceration, and Perforation

NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events.

CONTRAINDICATIONS

LICART is contraindicated in the following patients:

Known hypersensitivity to diclofenac or any components of the drug product.
History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.
In the setting of CABG surgery.
For use on non-intact or damaged skin.

WARNINGS AND PRECAUTIONS

Hepatotoxicity: Inform patients of warning signs and symptoms of hepatotoxicity. Discontinue if abnormal liver tests persist or worsen or if clinical signs and symptoms of liver disease develop.
Hypertension: Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. Monitor blood pressure.
Heart Failure and Edema: Avoid use of LICART in patients with severe heart failure unless benefits are expected to outweigh risk of worsening heart failure.
Renal Toxicity: Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia. Avoid use of LICART in patients with advanced renal disease unless benefits are expected to outweigh risk of worsening renal function.
Anaphylactic Reactions: Seek emergency help if an anaphylactic reaction occurs.
Exacerbation of Asthma Related to Aspirin Sensitivity: LICART is contraindicated in patients with aspirin-sensitive asthma. Monitor patients with preexisting asthma (without aspirin sensitivity).
Serious Skin Reactions: Discontinue LICART at first appearance of skin rash or other signs of hypersensitivity.
Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Discontinue and evaluate clinically.
Fetal Toxicity: Limit use of NSAIDs, including LICART, between about 20 to 30 weeks in pregnancy due to the risk of oligohydramnios/fetal renal dysfunction. Avoid use of NSAIDs in women at about 30 weeks' gestation and later in pregnancy due to the risks of oligohydramnios/fetal renal dysfunction and premature closure of the fetal ductus arteriosus.
Hematologic Toxicity: Monitor hemoglobin or hematocrit in patients with any signs or symptoms of anemia.

ADVERSE REACTIONS

Most common adverse reactions for LICART are application site pruritus and other application site reactions.
To report SUSPECTED ADVERSE REACTIONS, contact IBSA Pharma Inc. at: 1-800-587-3513 or FDA at 1-800-FDA-1088 or fda.gov/medwatch.
For Full Prescribing Information, visit licart.com/wp-content/uploads/2026/04/20260408_Licart-Ped-Indication.pdf.